Targeting Keap1/Nrf2/ARE signaling pathway in multiple sclerosis
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61388971%3A_____%2F20%3A00537237" target="_blank" >RIV/61388971:_____/20:00537237 - isvavai.cz</a>
Alternative codes found
RIV/00216208:11110/20:10411507
Result on the web
<a href="https://www.sciencedirect.com/science/article/pii/S0014299920300650" target="_blank" >https://www.sciencedirect.com/science/article/pii/S0014299920300650</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.ejphar.2020.172973" target="_blank" >10.1016/j.ejphar.2020.172973</a>
Alternative languages
Result language
angličtina
Original language name
Targeting Keap1/Nrf2/ARE signaling pathway in multiple sclerosis
Original language description
Multiple sclerosis (MS) is a neurologic autoimmune disorder featured by chronic inflammation of the central nervous system, demyelination and axonal damage. Recently, the term ´oxinflammation´ has been proposed to depict the vicious circle of chronic inflammation and oxidative stress (OS). OS promotes demyelination and neurodegeneration directly, by oxidation of lipids, proteins, and DNA but also indirectly, by inducing a dysregulation of the immunity and favoring the state of pro-inflammatory response. Many of the actors of this delicately tuned network are controlled by Keap1/Nrf2/ARE signaling pathway, a principal regulator of antioxidant and phase II detoxification genes. This pathway also has a pivotal role in inflammation, and therefore possesses a great potential in the treatment of MS. The aim of this review is to provide the newest insights in the preclinical and clinical evidence of Nrf2 induction in the regeneration of the antioxidant response and attenuation of inflammation in MS. Preclinical studies have indicated that activators of this pathway, such as epigallocatechin gallate (EGCG), curcumin, melatonin, resveratrol, and sulforaphane might be a promising therapeutic option in amelioration of MS symptoms, nevertheless, the efficacy and safety of these compounds have to be confirmed in future clinical trials.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30103 - Neurosciences (including psychophysiology)
Result continuities
Project
<a href="/en/project/GA20-09732S" target="_blank" >GA20-09732S: The triggers of Proteobacteria dysbiosis and its role in the pathogenesis of immune-mediated and metabolic diseases</a><br>
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
European Journal of Pharmacology
ISSN
0014-2999
e-ISSN
—
Volume of the periodical
873
Issue of the periodical within the volume
APR 15
Country of publishing house
NL - THE KINGDOM OF THE NETHERLANDS
Number of pages
15
Pages from-to
172973
UT code for WoS article
000519533300008
EID of the result in the Scopus database
2-s2.0-85078936359